Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)

Da: GRACEcast

0 0 7 anni fa

00:00

05:33

Mi piace Mi piace

Download Embed

Info
Chat in Diretta Commenti

Medicina, #acquired, #cancer, #cancergrace, #dana, #egfr, #farber, #geoffrey, #grace, #gracecast, #inhibitor, #institute, #metastasis, #mutation, #oxnard, #progression, #resistance, #significant, #solitary, #t790m, #tki

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.